In summary, we report the first case in which amivantamab monotherapy led to notably improved clinical outcomes in a patient with NSCLC harboring rare EGFR-mutated (G719A, A289V) with leptomeningeal carcinomatosis, following progression on osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.